Abstract
The GPRC6A receptor is a recently “deorphanized” class C G protein–coupled receptor. We and others have shown that this receptor is coactivated by basic l-α-amino acids and divalent cations, whereas other groups have also suggested osteocalcin and testosterone to be agonists. Likewise, the GPRC6A receptor has been suggested to couple to multiple G protein classes albeit via indirect methods. Thus, the exact ligand preferences and signaling pathways are yet to be elucidated. In the present study, we generated a Chinese hamster ovary (CHO) cell line that stably expresses mouse GPRC6A. In an effort to establish fully the signaling properties of the receptor, we tested representatives of four previously reported GPRC6A agonist classes for activity in the Gq, Gs, Gi, and extracellular-signal regulated kinase signaling pathways. Our results confirm that GPRC6A is activated by basic l-α-amino acids and divalent cations, and for the first time, we conclusively show that these responses are mediated through the Gq pathway. We were not able to confirm previously published data demonstrating Gi- and Gs-mediated signaling; neither could we detect agonistic activity of testosterone and osteocalcin. Generation of the stable CHO cell line with robust receptor responsiveness and optimization of the highly sensitive homogeneous time resolved fluorescence technology allow fast assessment of Gq activation without previous manipulations like cotransfection of mutated G proteins. This cell-based assay system for GPRC6A is thus useful in high-throughput screening for novel pharmacological tool compounds, which are necessary to unravel the physiologic function of the receptor.
Footnotes
- Received May 8, 2013.
- Accepted September 5, 2013.
↵1 Current affiliation: Novozymes A/S, Krogshoejvej 36, 2880 Bagsvaerd, Denmark (V.K.B.)
↵2 Current affiliation: Department of Medicine, Duke University Medical Center, Durham, North Carolina (A.R.B.T.)
S.E.J., L.N.-L., and A.R.B.T. contributed equally to this work.
This work was supported by grants from the Danish Council for Independent Research Medical Sciences (H.B.-O., V.K.B., P.W.); the Investment Capital for University Research (UNIK) Food, Fitness and Pharma for Health and Disease program (H.B.-O.); the Carlsberg Foundation (S.S.); and the Drug Research Academy (A.R.B.T.).
- Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|